Advances in vaccine adjuvant development and future perspectives
| dc.contributor.author | Sinani, Genada | |
| dc.contributor.author | Şenel, Sevda | |
| dc.date.accessioned | 2025-08-14T17:35:21Z | |
| dc.date.available | 2025-08-14T17:35:21Z | |
| dc.date.issued | 2025 | |
| dc.department | Fakülteler, Eczacılık Fakültesi | |
| dc.description | Article number : 2517137 CODEN : DDELE | |
| dc.description.abstract | Use of highly purified antigens to improve vaccine safety has led to reduced immunogenicity and efficacy, resulting in the need for adjuvants to increase and/or modulate the immunogenicity of the vaccine. Despite the need for potent and safe vaccine adjuvants, currently, there are still very few adjuvants in licensed human vaccines. Advances in immunology and molecular biology, especially in the last decade, have allowed researchers to understand better how the adjuvants work and enhance immune responses. While aluminum salts are still the most widely used adjuvants, research has shifted toward the rational design of adjuvant systems containing immunostimulatory molecules. Application of systems biology, which is based on high-throughput technologies using mathematical and computational modeling, has provided a deeper understanding of the biological events elicited by vaccination as well as the influence of other factors such as sex, age, microbiota, genetics and metabolism on the immune response. By this means, it became possible to tailor potential vaccine adjuvants more precisely for a successful vaccine with enhanced efficacy, safety and protection. In this review, after describing the mechanism of action of the adjuvants, current adjuvants in licensed vaccines, as well as those under clinical development will be mentioned in detail. Finally, new approaches in vaccine adjuvant development using systems biology and artificial intelligence will be reviewed, and future directions in vaccine research in regard to efficacy, safety and quality aspects will be discussed. | |
| dc.identifier.citation | Sinani, G., & Şenel, S. (2025). Advances in vaccine adjuvant development and future perspectives. Drug Delivery, 32(1), 2517137. 10.1080/10717544.2025.2517137 | |
| dc.identifier.doi | 10.1080/10717544.2025.2517137 | |
| dc.identifier.issn | 1071-7544 | |
| dc.identifier.issue | 1 | |
| dc.identifier.pmid | 40536024 | |
| dc.identifier.scopus | 2-s2.0-105008518009 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12939/5893 | |
| dc.identifier.volume | 32 | |
| dc.identifier.wos | WOS:001511949800001 | |
| dc.identifier.wosquality | Q1 | |
| dc.indekslendigikaynak | PubMed | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.institutionauthor | Sinani, Genada | |
| dc.language.iso | en | |
| dc.publisher | Taylor and Francis Ltd. | |
| dc.relation.ispartof | Drug Delivery | |
| dc.relation.publicationcategory | Diğer | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Clinical trials | |
| dc.subject | licensed vaccine adjuvants | |
| dc.subject | mechanism of action | |
| dc.subject | metabolic and epigenetic adjuvants | |
| dc.subject | microbiota | |
| dc.subject | systems biology | |
| dc.subject | tissue-resident memory responses | |
| dc.title | Advances in vaccine adjuvant development and future perspectives | |
| dc.type | Article |
